PSB

Sound Biologics (Qilu Puget Sound Biotherapeutics) is a clinical-stage biotechnology company based in Bothell, Washington, focused on developing innovative antibody-based therapeutics for oncology and inflammatory diseases. The company utilizes its proprietary MabPair™ technology platform, which enables the co-production of two distinct monoclonal antibodies from a single cell line, offering a streamlined and cost-effective alternative to traditional bispecific antibodies or combination therapies. Its lead product, PSB205 (QL1706), a bifunctional therapy targeting PD-1 and CTLA-4, was approved in China in 2024 for the treatment of metastatic cervical cancer and is currently in late-stage clinical trials for other solid tumors. Sound Biologics continues to advance a diverse pipeline, including the dual-targeting biologic PSB219 for respiratory conditions and the PD-1 inhibitor PSB103, through its strategic partnership with Qilu Pharmaceutical.